Plasma levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell disease
| Autor: | J. B. Schnog, Ashley J. Duits, F. P. L. van der Dijs, Tom Teerlink, Frits A. J. Muskiet |
|---|---|
| Přispěvatelé: | Lifestyle Medicine (LM) |
| Jazyk: | angličtina |
| Rok vydání: | 2005 |
| Předmět: |
Adult
Male ACUTE CHEST SYNDROME medicine.medical_specialty Endothelium Arginine endothelium Hemoglobin Sickle Vascular Cell Adhesion Molecule-1 Anemia Sickle Cell asymmetric dimethylarginine (ADMA) THERAPY Nitric oxide PULMONARY-HYPERTENSION PATHWAY chemistry.chemical_compound nitric oxide Internal medicine medicine Humans FAILURE RATES ARGININE business.industry Vascular disease DEATH Hematology General Medicine Middle Aged medicine.disease Pulmonary hypertension Acute chest syndrome Pathophysiology medicine.anatomical_structure Endocrinology chemistry RISK-FACTORS Female sickle cell disease Nitric Oxide Synthase hemolysis business Asymmetric dimethylarginine |
| Zdroj: | Annals of Hematology, 84(5), 282-286. SPRINGER |
| ISSN: | 0939-5555 |
| Popis: | In recent years an important role has been ascribed to a reduced nitric oxide (NO) availability in the pathophysiology of sickle cell disease (SCD). Endogenously produced inhibitors of NO synthase, in particular asymmetric dimethylarginine (ADMA), are currently considered of importance in various vascular disease states characterized by reduced NO availability. We determined ADMA levels in plasma of 12 adult sickle cell patients (eight HbSS and four HbSC), and compared these to plasma levels in race- and age-matched controls. Sickle cell patients were characterized by strongly elevated levels of ADMA [HbSS: median 0.63 mu mol/l (interquartile range 0.54-0.85), HbSC: 0.43 mu mol/l (0.40-0.46), HbAA: 0.33 mu mol/l (0.32-0.35) p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink